Genetic Sensorineural Hearing Loss Clinical Presentation

  • Author: Stephanie A Moody Antonio, MD; Chief Editor: Arlen D Meyers, MD, MBA   more...
 
Updated: Mar 29, 2012
 

History

Genetic hearing loss may be congenital, prelingual, or postlingual in onset and may present with progressive, fluctuating, or stable patterns. Congenital hearing loss is potentially identifiable with newborn screening. High-risk indicators should be used to identify children who are at risk for developing hearing loss after birth. Attention to high-risk indicators, to achievement of speech and language milestones, and to the family history are essential in evaluating a child for hearing loss.

Failure to achieve the following speech and language milestones may indicate hearing loss and necessitate a hearing evaluation:[13]

  • Birth to 3 months
    • Startles to loud noise
    • Awakens to sounds
    • Blinks or widens eyes in response to noises
  • 3-4 months
    • Quiets to mother's voice
    • Stops playing, listens to new sounds
    • Looks for source of new sounds that are not in sight
  • 6-9 months
    • Enjoys musical toys
    • Coos and gurgles with inflection
    • Says "mama"
  • 12-15 months
    • Responds to his or her name and the word "no"
    • Follows simple requests
    • Uses expressive vocabulary of 3-5 words
    • Imitates some sounds
  • 18-24 months
    • Knows body parts
    • Uses expressive vocabulary with 2-word phrases (minimum of 20-50 words)
    • 50% of speech intelligible to strangers
  • By 36 months
    • Uses expressive vocabulary of 4- to 5-word sentences (approximately 500 words)
    • 80% of speech intelligible to strangers
    • Understands some verbs

Potential sources of acquired hearing loss should be considered including the following: in utero infection associated with genetic sensorineural hearing loss (SNHL; eg, toxoplasmosis, rubella, CMV infection, herpes, syphilis), hyperbilirubinemia at levels that require exchange transfusion, birth weight of less than 1500 g, bacterial meningitis, low Apgar scores (0-3 at 5 minutes, 0-6 at 10 minutes), respiratory distress (eg, due to meconium aspiration), mechanical ventilation for more than 10 days, and exposure to ototoxic medication (eg, gentamicin) administered for more than 5 days or used in combination with loop diuretics.

In older children, additional confounding factors include otitis media, mumps, measles, and head trauma. A history of visual impairment, syncope spells, kidney disease, or other system issues should be identified as potential indicators of a syndromic etiology. A detailed family history to identify affected parents, siblings, and relatives is imperative in the evaluation of the patient with hearing impairment.

Next

Physical

Because genetic sensorineural hearing loss (SNHL) is associated with effects on virtually every organ, the physician must be familiar with the constellation of physical findings that may elucidate the etiology of a patient's hearing impairment.

Physical examination should include a complete evaluation of the ears, nose, throat, head, and neck, along with an overall assessment of the child's general physical and neurologic status.

Findings associated with hearing loss include microtia or atresia of the ear canal, cleft lip or palate, craniofacial abnormalities (eg, micrognathia, facial asymmetry, microcephaly, or craniosynostosis), cranial nerve weakness, heterochromia of the iris or other abnormalities of the ocular structures, vision impairment, goiter, and skeletal abnormalities.

Previous
Next

Causes

Approximately 50% of all cases of congenital deafness are genetic. Approximately 70% of cases of hereditary deafness are nonsyndromic, and the remaining 30% are syndromic, associated with specific deformities or medical problems. Of nonsyndromic hearing losses, 75-85% are inherited in an autosomal recessive pattern, 15-20% are inherited in an autosomal dominant pattern, and 1-3% are inherited in an X-linked pattern. Genetic hearing loss is differentiated from acquired hearing loss with identification of a perinatal infection, such as toxoplasmosis, rubella, cytomegalovirus and herpes (TORCH), or another source such as trauma or noise. Although generally thought of as a childhood condition, genetic hearing loss can result in adult-onset hearing loss. A genetic basis or a genetic-environmental interaction appears to predispose some patients to noise or age-related hearing loss.

Syndromic hearing impairment

More than 400 genetic syndromes are associated with hearing impairment. These disorders are categorized as autosomal dominant, recessive, or X-linked.

Syndromic hearing impairment, autosomal dominant

  • Waardenburg syndrome is the most common cause of autosomal dominant syndromic hearing loss. The syndrome includes dystopia canthorum, a broad nasal root, confluence of the medial eyebrows, heterochromia irides, a white forelock, and bilateral or unilateral SNHL. Expressivity is extremely variable.
    • Four subtypes of Waardenburg syndrome are defined, as follows:
      • Type I includes dystopia canthorum (ie, lateral displacement of the inner canthus of the eye) and is caused by mutations in PAX3.
      • Type II is characterized by the absence of dystopia canthorum and is caused by mutations in MITF.
      • Type III has associated upper-limb abnormalities and is caused by mutations in PAX3.
      • Type IV is thought to be caused by mutations in EDNRB, EDN3, and SOX10, and patients with type IV have Hirschsprung disease.
  • Branchio-oto-renal syndrome is the second most common cause of autosomal dominant syndromic HL. This condition manifests as renal abnormalities, preauricular pits, deformed auricles, and lateral branchial cysts. The hearing loss may be conductive, SNHL, or mixed. Some patients have Mondini anomalies of the cochlea. Penetrance is high, but expressivity is extremely variable. Mutations in the EYA1, SIX1, and SIX5 genes have been identified.
  • Neurofibromatosis type 2 (NF2) is associated with vestibular schwannomas, meningiomas, ependymomas, juvenile cataracts, and other intracranial and spinal tumors. The gene for NF2 has been mapped to chromosome 22q12.2 and is thought to be a tumor-suppressor gene. It has about 50% penetrance. In the Wishart type of NF2, the disease manifests in childhood or early adulthood. As vestibular schwannomas and other tumors develop, this subtype becomes rapidly progressive and often severely disabling. In the Gardner type of NF2, disease is more limited, less disabling, and presents later (in the third or fourth decades) that it is in the Wishart type.
  • Sticker syndrome is defined by the association of cleft palate, progressive genetic sensorineural hearing loss (SNHL), and spondyloepiphyseal dysplasia (SED). Defects in COL result in 3 different types STL1 (COL2A1), STL2 (COL11A1), and STL3 (COL11A2). Related morbidity of SED includes atlantoaxial instability, scoliosis, osteoarthritis, myopia, and retinal detachment.
  • Otosclerosis is a genetic disorder generally associated with adult-onset conductive hearing loss. However, advanced otosclerosis may cause SNHL. The genes responsible for otosclerosis have not been found, but foci on chromosomes 6, 7, and 15 have been implicated.
  • Achondroplasia may be associated with mixed hearing loss.
  • Paget disease may result in progressive, adult-onset conductive hearing loss, genetic sensorineural hearing loss (SNHL), or both. Other common findings of this bone disorder are enlargement of the skull, kyphosis, and shortening of stature. The hearing loss is thought to be due to a cochlear process. Genetic and environmental factors are likely to be contributing factors.

Syndromic hearing impairment, autosomal recessive

  • Usher syndrome is the most common cause of autosomal recessive syndromic SNHL. Usher syndrome results in both hearing and visual impairments, and it is the etiology in at least 50% of persons with deafness and blindness. It may represent 3-6% of children born deaf and an additional 3-6% of children with milder hearing loss. The incidence is 4 in 100,000 births.
    • Three main types of Usher syndrome are described, as follows:
      • Type I is characterized by congenital severe-profound hearing loss and vestibular dysfunction. Retinitis pigmentosa (RP) develops in childhood and progresses from night blindness and loss of peripheral vision to blindness, through progressive degeneration of the retina. Vestibular dysfunction results in delayed motor milestones and may not walk until after 18 months.
      • Type II Usher syndrome is characterized by congenital mild-to-severe SNHL but normal vestibular function. Associate RP develops during the later teen years and tends to progress slower than in type I.
      • Children with Type III Ushers have normal hearing at birth that progresses during the teen years, requiring hearing aids by adulthood. Vestibular function is usually fairly normal, but may decline over time. RP begins at puberty and progresses into adulthood.
    • Early diagnosis is important in Usher syndrome and will impact management. Patients with Type I Usher syndrome who rely on manual communication may be more significantly impacted with development of visual impairment, at which time auditory rehabilitation will be less complete than if initiated earlier. Electroretinogram can be performed after the age of 2 years and may aid in identifying retinal problems earlier than fundoscopic examination and visual field tests. Genetic testing is now available and should be considered. Early identification and early cochlear implantation may mitigate the effect of dual sensory impairment if auditory-oral skills are developed prior to the onset of visual impairment.[14]
    • Twelve loci have been found to cause Usher syndrome. Genes and the proteins that they encode have been identified for 7 of the 12 loci. The genes that cause Usher syndrome are MY07A, USH1C, CDH23, PCDH15, and SANS, which cause USH1, USH2A (which causes USH2), and USH3A (which causes USH3). A mutation, named R245X, of the PCDH15 gene may account for a large percentage of USH1 cases in today's Ashkenazi Jewish population.
  • Pendred syndrome is the second most common type of AR syndromic hearing loss. It is characterized by congenital severe-to-profound sensorineural hearing impairment and euthyroid goiter. Goiter develops in early puberty or adulthood. Affected individuals have an abnormal perchlorate test indicating delayed organification of iodine by the thyroid. Mondini dysplasia and dilated vestibular aqueduct are commonly found during radiographic evaluation. Mutations in SLC26A4, which codes for pendrin, have been identified. Genetic testing is available and can be suggested if a Mondini malformation is found during evaluation.
  • Jervell and Lange-Nielsen syndrome results in congenital genetic sensorineural hearing loss (SNHL) and a prolonged QT interval. Affected individuals have syncopal episodes and may have sudden death. High-risk children (ie, those with a family history that is positive for sudden death, SIDS, syncopal episodes, or long QT syndrome) should have a thorough cardiac evaluation. EKG is commonly included in screening protocols for congenital hearing loss.
    • Mutations in the KCNE1 and KCNQ1 genes cause Jervell and Lange-Nielsen syndrome. About 90% of cases of Jervell and Lange-Nielsen syndrome are caused by mutations in the KCNQ1 gene; KCNE1 mutations are responsible for the remaining 10% of cases.
    • These genes are responsible for coding potassium channel proteins critical for maintaining the normal functions of the inner ear and cardiac muscle. Mutations in these genes alter the usual structure and function of potassium channels or prevent the assembly of normal channels. These changes disrupt the flow of potassium ions in the inner ear and in cardiac muscle, leading to the hearing loss and irregular heart rhythm characteristic of Jervell and Lange-Nielsen syndrome.
  • Refsum disease is a rare condition manifested by severe progressive genetic sensorineural hearing loss (SNHL) and retinitis pigmentosa due to abnormal phytanic acid metabolism. Because it can be treated with dietary modification and plasmapheresis, identification may be helpful

X-linked syndromic hearing loss

  • Alport syndrome is a result of mutations in type IV collagen genes that result in faulty basement membranes of the kidney and cochlea. The incidence is thought to be 1 in 5000 persons and is more common in males. The HL is bilateral and slowly progressive often starting in late childhood in the high frequencies. Deafness is common by age 25 years. In males, proteinuria progresses to end-stage renal disease before age 40 years.
    • In females, end-stage renal disease is less frequent until later decades. Diagnostic criteria include family history of hematuria progressing to end-stage renal disease, progressive high frequency genetic sensorineural hearing loss (SNHL), thickening of the renal basement membrane by electron microscopy, and anterior lenticonus and perimacular flecks.
    • In 80% of patients with Alport syndrome, the inheritance is X-linked dominant. Patients with Alport syndrome have mutations in COL4A3, COL4A4, or COL4A5 near Xq22. Other forms are autosomal dominant or recessive and, in these cases, the severity is equal between the sexes.

Nonsyndromic genetic sensorineural hearing loss

An estimated 70-80% of hereditary hearing loss is nonsyndromic. Approximately 75% of nonsyndromic genetic sensorineural hearing loss (SNHL) is autosomal recessive, 15-20% is autosomal dominant, and 1-3% is X-linked. As highlighted by Van Laer et al, some genes may be associated with both autosomal dominant and recessive hearing loss. Some variability may be seen in the phenotype, based on the location and type of mutation of a gene and effects of modifying genes and environmental factors.[15]

When a gene locus for hearing loss is identified, it is named for the inheritance pattern and a consecutive number. DFNA indicates autosomal dominant gene loci, DFNB indicates autosomal recessive loci, and DFN indicates X-linked loci.[16] Mitochondrial disorders also exist. New gene loci are discovered every year.

Autosomal recessive nonsyndromic hearing loss is usually prelingual, nonprogressive, and severe to profound. Mutations in the connexin 26 gene at locus DFNB1 on chromosome 13 are thought to account for about 50% of recessive nonsyndromic hearing loss. 35delG is the most common mutation, but at least 90 different GJB2 mutations have been described.[17]

The gene GJB2 codes for connexin 26, a gap junction beta2 protein. These proteins form intercellular channels in the plasma membrane and facilitate the exchange of molecules between cells. Connexin 26 is expressed in the stria vascularis, spiral ligament, spiral limbus, and in supporting cells of the cochlea. It appears to have a role in recycling of potassium. The hearing loss is usually prelingual and varies from mild to profound. It is usually predominantly high frequency and sloping but may also present with a flat audiometric curve. It is most often bilateral and symmetric, but unilateral cases have been identified. The ear is usually radiologically normal. Connexin 26-related hearing loss can be inherited by autosomal recessive or dominant patterns.

Autosomal dominant nonsyndromic hearing loss is more likely to be postlingual than autosomal recessive nonsyndromic hearing loss and is more variable in frequency distribution and severity. A common X-linked nonsyndromic mutation at gene locus DFN3 causes a mixed hearing loss. These patients are prone to perilymph gushers during stapedectomy that will result in profound postoperative SNHL. The related gene is POU3F4.

An interesting mitochondrial gene mutation is that for aminoglycoside-induced genetic sensorineural hearing loss (SNHL). The mutation A1555G in the 12s rRNA gene makes a person susceptible to hearing loss after treatment with gentamicin, neomycin, or other aminoglycosides.

Several websites are devoted to cataloging gene mutations, including The Hereditary Hearing Loss Homepage and those of the Harvard Medical School Center for Hereditary Deafness and GeneTests.

Previous
 
 
Contributor Information and Disclosures
Author

Stephanie A Moody Antonio, MD  Assistant Professor, Department of Otolaryngology-Head and Neck Surgery, Eastern Virginia Medical School

Stephanie A Moody Antonio, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American Medical Association, American Neurotology Society, and Virginia Society of Otolaryngology-Head and Neck Surgery

Disclosure: Nothing to disclose.

Coauthor(s)

Barry Strasnick, MD, FACS  Chairman, Professor, Department of Otolaryngology-Head and Neck Surgery, Eastern Virginia Medical School

Barry Strasnick, MD, FACS is a member of the following medical societies: Alpha Omega Alpha, American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, American Auditory Society, American College of Surgeons, American Medical Association, American Tinnitus Association, Ear Foundation Alumni Society, Norfolk Academy of Medicine, North American Skull Base Society, Society of University Otolaryngologists-Head and Neck Surgeons, Vestibular Disorders Association, and Virginia Society of Otolaryngology-Head and Neck Surgery

Disclosure: Nothing to disclose.

Specialty Editor Board

Robert A Battista, MD, FACS  Assistant Professor of Otolaryngology, Northwestern University, The Feinberg School of Medicine; Physician, Ear Institute of Chicago, LLC

Robert A Battista, MD, FACS is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Neurotology Society, and Illinois State Medical Society

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Gerard J Gianoli, MD  Clinical Associate Professor, Department of Otolaryngology-Head and Neck Surgery, Tulane University School of Medicine; Vice President, The Ear and Balance Institute; Chief Executive Officer, Ponchartrain Surgery Center

Gerard J Gianoli, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Neurotology Society, American Otological Society, Society of University Otolaryngologists-Head and Neck Surgeons, and Triological Society

Disclosure: Vesticon, Inc. None Board membership

Christopher L Slack, MD  Private Practice in Otolaryngology and Facial Plastic Surgery, Associated Coastal ENT; Medical Director, Treasure Coast Sleep Disorders

Christopher L Slack, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, and American Medical Association

Disclosure: Nothing to disclose.

Chief Editor

Arlen D Meyers, MD, MBA  Professor of Otolaryngology, Dentistry, and Engineering, University of Colorado School of Medicine

Arlen D Meyers, MD, MBA is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, and American Head and Neck Society

Disclosure: Covidien Corp Consulting fee Consulting; US Tobacco Corporation Unrestricted gift Unknown; Axis Three Corporation Ownership interest Consulting; Omni Biosciences Ownership interest Consulting; Sentegra Ownership interest Board membership; Medvoy Ownership interest Management position; Cerescan Imaging Consulting; Headwatersmb Consulting fee Consulting; Venturequest Royalty Consulting

Additional Contributors

The authors and editors of eMedicine gratefully acknowledge the contributions of previous author Karen K Hoffmann, MD, to the development and writing of this article.

References
  1. Eisen MD, Ryugo DK. Hearing molecules: contributions from genetic deafness. Cell Mol Life Sci. Mar 2007;64(5):566-80. [Medline]. [Full Text].

  2. Vrijens K, Van Laer L, Van Camp G. Human hereditary hearing impairment: mouse models can help to solve the puzzle. Hum Genet. Nov 2008;124(4):325-48. [Medline].

  3. Van Camp G, SmithR. Cloned genes for nonsyndromic hearing impairment. Hereditary Hearing Loss Homepage. Available at http://hereditaryhearingloss.org/. Accessed 04/14/09.

  4. Brini M, Di Leva F, Domi T, Fedrizzi L, Lim D, Carafoli E. Plasma-membrane calcium pumps and hereditary deafness. Biochem Soc Trans. Nov 2007;35 (pt 5):913-8.

  5. Xing G, Chen Z, Cao X. Mitochondrial rRNA and tRNA and hearing function. Cell Res. Mar 2007;17(3):227-39. [Medline]. [Full Text].

  6. El-Amraoui A, Petit C. Usher I syndrome: unravelling the mechanisms that underlie the cohesion of the growing hair bundle in inner ear sensory cells. j cell sci. 2005/10;118(Pt 20):4593-603. [Full Text].

  7. Mehra S, Eavey RD, Keamy DG Jr. The epidemiology of hearing impairment in the United States: newborns, children, and adolescents. Otolaryngol Head Neck Surg. Apr 2009;140(4):461-72. [Medline].

  8. Saunders JE, Vaz S, Greinwald JH, Lai J, Morin L, Mojica K. Prevalence and etiology of hearing loss in rural Nicaraguan children. Laryngoscope. Mar 2007;117(3):387-98. [Medline].

  9. Ouyang XM, Yan D, Yuan HJ, et al. The genetic basis of non-syndromic hearing loss among Chinese. J Hum Genet. 2009;54(3):131-40.

  10. Angeli SI. Phenotype/genotype correlations in a DFNB1 cohort with ethnical diversity. Laryngoscope. Nov 2008;118(11):2014-23. [Medline].

  11. Schimmenti LA, Martinez A, Telatar M, et al. Infant hearing loss and connexin testing in a diverse population. Genet Med. Jul 2008;10(7):517-24. [Medline].

  12. Korres S, Nikolopoulos TP, Komkotou V, et al. Newborn hearing screening: effectiveness, importance of high-risk factors, and characteristics of infants in the neonatal intensive care unit and well-baby nursery. Otol Neurotol. Nov 2005;26(6):1186-90. [Medline].

  13. Northern JL, Downs MP. Hearing in Children. 4th ed. Baltimore, Md: Williams & Wilkins; 1991:28-31.

  14. Liu XZ, Angeli SI, Rajput K, et al. Cochlear implantation in individuals with Usher type 1 syndrome. Int J Pediatr Otorhinolaryngol. Jun 2008;72(6):841-7. [Medline].

  15. Van Laer L, Cryns K, Smith RJ, Van Camp G. Nonsyndromic hearing loss. Ear Hear. Aug 2003;24(4):275-88. [Medline].

  16. Topsakal V, Hilgert N, van Dinther J, Tranebjaerg L, Rendtorff ND, Zarowski A, et al. Genotype-phenotype correlation for DFNA22: characterization of non-syndromic, autosomal dominant, progressive sensorineural hearing loss due to MYO6 mutations. Audiol Neurootol. 2010;15(4):211-20. [Medline].

  17. Karamert R, Bayazit YA, Altinyay S, Yilmaz A, Menevse A, Gokdogan O, et al. Association of GJB2 gene mutation with cochlear implant performance in genetic non-syndromic hearing loss. Int J Pediatr Otorhinolaryngol. Dec 2011;75(12):1572-5. [Medline].

  18. Usami SI, Nishio SY, Nagano M, Abe S, Yamaguchi T. Simultaneous Screening of Multiple Mutations by Invader Assay Improves Molecular Diagnosis of Hereditary Hearing Loss: A Multicenter Study. PLoS One. 2012;7(2):e31276. [Medline]. [Full Text].

  19. Nadol JB Jr, Merchant SN. Histopathology and molecular genetics of hearing loss in the human. Int J Pediatr Otorhinolaryngol. Oct 19 2001;61(1):1-15. [Medline].

  20. Arnos Kathleen. Ethical and social implications of genetic testing for communication disorders. Journal of Communication Disorders. September-October 2008;41:444-457.

  21. Anagnostakis D, Petmezakis J, Papazissis G, Messaritakis J, Matsaniotis N. Hearing loss in low-birth-weight infants. Am J Dis Child. Jul 1982;136(7):602-4. [Medline].

  22. Bergstrom L, Hemenway WG, Downs MP. A high risk registry to find congenital deafness. Otolaryngol Clin North Am. Jun 1971;4(2):369-99. [Medline].

  23. Cohn ES, Kelley PM, Fowler TW, et al. Clinical studies of families with hearing loss attributable to mutations in the connexin 26 gene (GJB2/DFNB1). Pediatrics. Mar 1999;103(3):546-50. [Medline].

  24. Cunningham M, Cox EO. Hearing assessment in infants and children: recommendations beyond neonatal screening. Pediatrics. Feb 2003;111(2):436-40. [Medline].

  25. Dahle AJ, McCollister FP, Hamner BA, Reynolds DW, Stagno S. Subclinical congenital cytomegalovirus infection and hearing impairment. J Speech Hear Disord. Aug 1974;39(3):320-9. [Medline].

  26. Davidson J, Hyde ML, Alberti PW. Epidemiologic patterns in childhood hearing loss: a review. Int J Pediatr Otorhinolaryngol. Jul 1989;17(3):239-66. [Medline].

  27. DeStefano AL, Gates GA, Heard-Costa N, Myers RH, Baldwin CT. Genomewide linkage analysis to presbycusis in the Framingham Heart Study. Arch Otolaryngol Head Neck Surg. Mar 2003;129(3):285-9. [Medline].

  28. Downs MP. Benefits of screening at birth: economic, educational and functional factors. In: NIH Consensus Development Conference. 1993:63-6.

  29. Erenberg A, Lemons J, Sia C, Trunkel D, Ziring P. Newborn and infant hearing loss: detection and intervention.American Academy of Pediatrics. Task Force on Newborn and Infant Hearing, 1998- 1999. Pediatrics. Feb 1999;103(2):527-30. [Medline].

  30. Fraser GR. The Causes of Profound Deafness in Children. Baltimore, Md: Johns Hopkins University Press; 1976.

  31. Friedrick B. The state of art in audiologic evaluation and management. In: Cherow E, Matkin ND, Trybus RJ, eds. Hearing-Impaired Children and Youth with Developmental Disabilities: an Interdisciplinary Foundation for Service. Washington, DC: Gallaudet College Press; 1985:122-5.

  32. Gates GA, Couropmitree NN, Myers RH. Genetic associations in age-related hearing thresholds. Arch Otolaryngol Head Neck Surg. Jun 1999;125(6):654-9. [Medline].

  33. Jackler RK, Luxford WM, House WF. Congenital malformations of the inner ear: a classification based on embryogenesis. Laryngoscope. Mar 1987;97(3 Pt 2 Suppl 40):2-14. [Medline].

  34. Jackler RK, Luxford WM, House WF. Congenital malformations of the inner ear: a classification based on embryogenesis. Laryngoscope. Mar 1987;97(3 Pt 2 Suppl 40):2-14. [Medline].

  35. Kenna MA, Wu BL, Cotanche DA, Korf BR, Rehm HL. Connexin 26 studies in patients with sensorineural hearing loss. Arch Otolaryngol Head Neck Surg. Sep 2001;127(9):1037-42. [Medline].

  36. Kenneson A, Van Naarden Braun K, Boyle C. GJB2 (connexin 26) variants and nonsyndromic sensorineural hearing loss: a HuGE review. Genet Med. Jul-Aug 2002;4(4):258-74. [Medline].

  37. Marlin S, Garabedian EN, Roger G, et al. Connexin 26 gene mutations in congenitally deaf children: pitfalls for genetic counseling. Arch Otolaryngol Head Neck Surg. Aug 2001;127(8):927-33. [Medline].

  38. Mauk GW, White KR, Mortensen LB, Behrens TR. The effectiveness of screening programs based on high-risk characteristics in early identification of hearing impairment. Ear Hear. Oct 1991;12(5):312-9. [Medline].

  39. Nance WE, Sweeney A. Symposium on sensorineural hearing loss in children: early detection and intervention. Genetic factors in deafness of early life. Otolaryngol Clin North Am. Feb 1975;8(1):19-48. [Medline].

  40. Northern JL. Impedance measurement in infants. In: Mencher GT, Gerber SE, eds. Early Management of Hearing Loss. New York, NY: Grune & Stratton; 1981:131-49.

  41. Northern JL. Universal screening for infant hearing impairment. Pediatrics. Dec 1994;94(6 Pt 1):955; author reply 959-63. [Medline].

  42. Northern JL, Hayes D. Universal screening for infant hearing impairment: necessary, beneficial and justifiable. Audiol Today. 1994;6:10-13.

  43. Paparella MM, Sugiura S, Hoshino T. Familial progressive sensorineural deafness. Arch Otolaryngol. Jul 1969;90(1):44-51. [Medline].

  44. Pass RF, Stagno S, Myers GJ, Alford CA. Outcome of symptomatic congenital cytomegalovirus infection: results of long-term longitudinal follow-up. Pediatrics. Nov 1980;66(5):758-62. [Medline].

  45. Schuknecht HF. Pathology of the Ear. Philadelphia, Pa: Lea & Febiger; 1993.

  46. Skvorak Giersch AB, Morton CC. Genetic causes of nonsyndromic hearing loss. Curr Opin Pediatr. Dec 1999;11(6):551-7. [Medline].

  47. Smith Richard JH, Van Camp G. Deafness and Hereditary Hearing Loss, Overview. gene reviews. 2005;[Full Text].

  48. Smith Richard JH, Van Camp Guy. Deafness and Hereditary Hearing Loss Overview. geneReviews. Available at http://www.geneclinics.org/profiles/deafness-overview/details.html. Accessed December 22, 2008.

  49. Snoeckx RL, Huygen PL, Feldmann D, et al. GJB2 mutations and degree of hearing loss: a multicenter study. Am J Hum Genet. Dec 2005;77(6):945-57. [Medline].

  50. Stein L, Clark S, Kraus N. The hearing-impaired infant: patterns of identification and habilitation. Ear Hear. Sep-Oct 1983;4(5):232-6. [Medline].

  51. Stein LK, Jabaley T, Spitz R, Stoakley D, McGee T. The hearing-impaired infant: patterns of identification and habilitation revisited. Ear Hear. Jun 1990;11(3):201-5. [Medline].

  52. Tseng CJ, Lalwani AK. Cracking the auditory genetic code: part II. Syndromic hereditary hearing impairment. Am J Otol. May 2000;21(3):437-51. [Medline].

  53. Wilson J. Deafness in developing countries. Approaches to a global program of prevention. Arch Otolaryngol. Jan 1985;111(1):2-9. [Medline].

Previous
Next
 
Inner ear.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.